ACADIA Pharmaceuticals Inc.
ACAD
Rang in Aktien
#4511
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aktienkurs
$19.76
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$3.40B
Veränderung (1 Tag)
3.32%
Veränderung (1 Jahr)
-5.66%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von ACADIA Pharmaceuticals Inc. (ACAD)
Anzahl der ausstehenden Aktien zum June 2026: 171.60M
Laut den neuesten Finanzberichten und dem Aktienkurs von ACADIA Pharmaceuticals Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 171.60M. Am Ende von December 2023 hatte das Unternehmen 163.82M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von ACADIA Pharmaceuticals Inc. (ACAD) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 171.60M | 3.55% |
| 2024 | 165.72M | 1.16% |
| 2023 | 163.82M | 1.32% |
| 2022 | 161.68M | 0.74% |
| 2021 | 160.49M | 2.01% |
| 2020 | 157.33M | 6.88% |
| 2019 | 147.20M | 16.29% |
| 2018 | 126.58M | 3.25% |
| 2017 | 122.60M | 5.82% |
| 2016 | 115.86M | 15.13% |
| 2015 | 100.63M | 3.48% |
| 2014 | 97.25M | 13.46% |
| 2013 | 85.72M | 56.23% |
| 2012 | 54.87M | 5.14% |
| 2011 | 52.18M | 35.21% |
| 2010 | 38.59M | 2.98% |
| 2009 | 37.48M | 0.98% |
| 2008 | 37.11M | 5.40% |
| 2007 | 35.21M | 26.10% |
| 2006 | 27.92M | 26.84% |
| 2005 | 22.01M | 112.63% |
| 2004 | 10.35M | 609.62% |
| 2003 | 1.46M | 0.48% |
| 2002 | 1.45M | 20.20% |
| 2001 | 1.21M | 12.90% |
| 2000 | 1.07M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 47.96% |
US
|
|
| 396.00M | 130.77% |
US
|
|
| 478.91M | 179.08% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.76% |
NL
|
